DE2760410C2 - - Google Patents
Info
- Publication number
- DE2760410C2 DE2760410C2 DE2760410A DE2760410A DE2760410C2 DE 2760410 C2 DE2760410 C2 DE 2760410C2 DE 2760410 A DE2760410 A DE 2760410A DE 2760410 A DE2760410 A DE 2760410A DE 2760410 C2 DE2760410 C2 DE 2760410C2
- Authority
- DE
- Germany
- Prior art keywords
- verbenon
- fraction
- effect
- sobrerol
- preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- OMDMTHRBGUBUCO-IUCAKERBSA-N (1s,5s)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol Chemical compound CC1=CC[C@H](C(C)(C)O)C[C@@H]1O OMDMTHRBGUBUCO-IUCAKERBSA-N 0.000 description 16
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 235000007586 terpenes Nutrition 0.000 description 9
- 229960000230 sobrerol Drugs 0.000 description 8
- 150000003505 terpenes Chemical class 0.000 description 8
- OMDMTHRBGUBUCO-UHFFFAOYSA-N trans-sobrerol Natural products CC1=CCC(C(C)(C)O)CC1O OMDMTHRBGUBUCO-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- DCSCXTJOXBUFGB-JGVFFNPUSA-N (R)-(+)-Verbenone Natural products CC1=CC(=O)[C@@H]2C(C)(C)[C@H]1C2 DCSCXTJOXBUFGB-JGVFFNPUSA-N 0.000 description 5
- DCSCXTJOXBUFGB-SFYZADRCSA-N (R)-(+)-verbenone Chemical compound CC1=CC(=O)[C@H]2C(C)(C)[C@@H]1C2 DCSCXTJOXBUFGB-SFYZADRCSA-N 0.000 description 5
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 5
- DCSCXTJOXBUFGB-UHFFFAOYSA-N verbenone Natural products CC1=CC(=O)C2C(C)(C)C1C2 DCSCXTJOXBUFGB-UHFFFAOYSA-N 0.000 description 5
- KMRMUZKLFIEVAO-UHFFFAOYSA-N 7,7-dimethylbicyclo[3.1.1]hept-3-ene-4-carbaldehyde Chemical compound C1C2C(C)(C)C1CC=C2C=O KMRMUZKLFIEVAO-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KMRMUZKLFIEVAO-RKDXNWHRSA-N Myrtenal Natural products C1[C@H]2C(C)(C)[C@@H]1CC=C2C=O KMRMUZKLFIEVAO-RKDXNWHRSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940117975 chromium trioxide Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- RXBQNMWIQKOSCS-UHFFFAOYSA-N (7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methanol Chemical compound C1C2C(C)(C)C1CC=C2CO RXBQNMWIQKOSCS-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000779819 Syncarpia glomulifera Species 0.000 description 2
- WONIGEXYPVIKFS-UHFFFAOYSA-N Verbenol Chemical compound CC1=CC(O)C2C(C)(C)C1C2 WONIGEXYPVIKFS-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000003555 analeptic effect Effects 0.000 description 2
- 230000002744 anti-aggregatory effect Effects 0.000 description 2
- 230000002322 anti-exudative effect Effects 0.000 description 2
- 230000003182 bronchodilatating effect Effects 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- -1 chromium trioxide Ketones Chemical class 0.000 description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108700025647 major vault Proteins 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000001739 pinus spp. Substances 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 229940036248 turpentine Drugs 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- IRZWAJHUWGZMMT-UHFFFAOYSA-N Chrysanthenol Natural products CC1=CCC2C(C)(C)C1C2O IRZWAJHUWGZMMT-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RXBQNMWIQKOSCS-RKDXNWHRSA-N Myrtenol Natural products C1[C@H]2C(C)(C)[C@@H]1CC=C2CO RXBQNMWIQKOSCS-RKDXNWHRSA-N 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/81—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
- C07C45/82—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation by distillation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH704276A CH625197A5 (en) | 1976-06-03 | 1976-06-03 | Process for preparing verbenone, myrtenal and pinocarveol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2760410C2 true DE2760410C2 (enrdf_load_stackoverflow) | 1990-08-16 |
Family
ID=4319020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2725247A Expired DE2725247C2 (de) | 1976-06-03 | 1977-06-03 | Verfahren zur Herstellung von Verbenon bzw. Myrtenal |
| DE2760410A Expired - Fee Related DE2760410C2 (enrdf_load_stackoverflow) | 1976-06-03 | 1977-06-03 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2725247A Expired DE2725247C2 (de) | 1976-06-03 | 1977-06-03 | Verfahren zur Herstellung von Verbenon bzw. Myrtenal |
Country Status (25)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04239414A (ja) * | 1991-01-24 | 1992-08-27 | Sekisui Chem Co Ltd | 粘着テープを使用した結束装置及び結束方法 |
| IT1251615B (it) * | 1991-10-04 | 1995-05-17 | Golgi Sa | Medicamento ad attivita' antielastasica. |
| IT1312537B1 (it) * | 1999-04-16 | 2002-04-22 | Euphar Group Srl | Derivati del (-)- verbenone. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE784885A (fr) * | 1971-06-14 | 1972-10-02 | Buskine Sa | Melanges terpeniques, utiles en therapeutique, et leur procede de preparation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1103814A (fr) * | 1953-04-30 | 1955-11-07 | Glidden Co | Perfectionnements relatifs au traitement des mélanges et produits d'auto-oxydation du terpène |
| US2911442A (en) * | 1953-04-30 | 1959-11-03 | Glidden Co | Production of oxygenated terpenes from alpha-pinene |
| FR1377525A (fr) * | 1963-09-25 | 1964-11-06 | Centre Nat Rech Scient | Procédé de préparation de cétones terpéniques |
| FR1572146A (enrdf_load_stackoverflow) * | 1967-05-10 | 1969-06-27 | ||
| US3673066A (en) * | 1969-02-14 | 1972-06-27 | Lab De L Ozothine | Process for the accelerated obtaining of terpenic oxides using ultraviolet light |
| CH523962A (fr) * | 1969-08-18 | 1972-06-15 | Int Flavors & Fragrances Inc | Utilisation de dérivés d'indane comme principes odorants |
| FR2267296A1 (en) * | 1974-04-12 | 1975-11-07 | Anvar | Myrtenol synthesis - by isomerisation of beta-pinene epoxide |
-
1976
- 1976-06-03 CH CH704276A patent/CH625197A5/it not_active IP Right Cessation
-
1977
- 1977-05-25 GB GB22089/77A patent/GB1585831A/en not_active Expired
- 1977-05-25 GB GB1504/80A patent/GB1585832A/en not_active Expired
- 1977-05-31 NL NL7705934A patent/NL7705934A/xx not_active Application Discontinuation
- 1977-05-31 PT PT66619A patent/PT66619B/pt unknown
- 1977-05-31 CS CS773586A patent/CS251755B2/cs unknown
- 1977-06-01 CA CA279,610A patent/CA1099214A/en not_active Expired
- 1977-06-01 AU AU25732/77A patent/AU519521B2/en not_active Expired
- 1977-06-01 SE SE7706385A patent/SE424723B/xx unknown
- 1977-06-01 BE BE178116A patent/BE855297A/xx unknown
- 1977-06-01 NO NO771926A patent/NO771926L/no unknown
- 1977-06-02 PL PL1977198600A patent/PL116550B1/pl unknown
- 1977-06-02 DK DK244277A patent/DK244277A/da not_active Application Discontinuation
- 1977-06-02 FI FI771765A patent/FI771765A7/fi not_active Application Discontinuation
- 1977-06-02 HU HU77CO341A patent/HU178205B/hu unknown
- 1977-06-02 JP JP6404177A patent/JPS52151156A/ja active Pending
- 1977-06-02 ES ES459425A patent/ES459425A1/es not_active Expired
- 1977-06-02 SU SU772494040A patent/SU816396A3/ru active
- 1977-06-03 DE DE2725247A patent/DE2725247C2/de not_active Expired
- 1977-06-03 ZA ZA00773345A patent/ZA773345B/xx unknown
- 1977-06-03 DD DD7700199291A patent/DD130475A1/xx unknown
- 1977-06-03 IT IT24385/77A patent/IT1074511B/it active Protection Beyond IP Right Term
- 1977-06-03 OA OA56187A patent/OA05678A/xx unknown
- 1977-06-03 DE DE2760410A patent/DE2760410C2/de not_active Expired - Fee Related
- 1977-06-03 FR FR7717088A patent/FR2416878A1/fr not_active Withdrawn
- 1977-06-03 AT AT394077A patent/AT351520B/de not_active IP Right Cessation
- 1977-06-08 AR AR267933A patent/AR214200A1/es active
-
1981
- 1981-05-06 FR FR8108999A patent/FR2479804A1/fr not_active Withdrawn
- 1981-09-25 SE SE8105687A patent/SE8105687L/sv not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE784885A (fr) * | 1971-06-14 | 1972-10-02 | Buskine Sa | Melanges terpeniques, utiles en therapeutique, et leur procede de preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| AU519521B2 (en) | 1981-12-10 |
| PL116550B1 (en) | 1981-06-30 |
| FI771765A7 (enrdf_load_stackoverflow) | 1977-12-04 |
| AU2573277A (en) | 1978-12-07 |
| PL198600A1 (pl) | 1978-06-19 |
| PT66619A (fr) | 1977-06-01 |
| ATA394077A (de) | 1979-01-15 |
| PT66619B (fr) | 1978-10-27 |
| BE855297A (fr) | 1977-10-03 |
| FR2479804A1 (fr) | 1981-10-09 |
| FR2416878A1 (fr) | 1979-09-07 |
| GB1585831A (en) | 1981-03-11 |
| NL7705934A (nl) | 1977-12-06 |
| DK244277A (da) | 1977-12-04 |
| CA1099214A (en) | 1981-04-14 |
| CS251755B2 (en) | 1987-08-13 |
| OA05678A (fr) | 1981-05-31 |
| NO771926L (no) | 1977-12-06 |
| DE2725247C2 (de) | 1987-02-12 |
| AT351520B (de) | 1979-07-25 |
| SU816396A3 (ru) | 1981-03-23 |
| CH625197A5 (en) | 1981-09-15 |
| SE424723B (sv) | 1982-08-09 |
| JPS52151156A (en) | 1977-12-15 |
| SE8105687L (sv) | 1981-09-25 |
| DD130475A1 (de) | 1978-04-05 |
| IT1074511B (it) | 1985-04-20 |
| SE7706385L (sv) | 1977-12-04 |
| AR214200A1 (es) | 1979-05-15 |
| ES459425A1 (es) | 1978-04-01 |
| ZA773345B (en) | 1978-04-26 |
| HU178205B (en) | 1982-03-28 |
| DE2725247A1 (de) | 1977-12-22 |
| GB1585832A (en) | 1981-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2501443C2 (de) | Pharmazeutische Mittel mit einem Gehalt an mindestens einer diphenylsubstituierten Verbindung | |
| DD148951A5 (de) | Verfahren zur herstellung virozider aminderivate | |
| DE2760410C2 (enrdf_load_stackoverflow) | ||
| EP0501206B1 (de) | Phenonverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| DE2019504C3 (de) | Oxim-N-acylcarbamate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Schädlingsbekämpfung | |
| DE69424816T2 (de) | N-Benzylpiperazinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende Zusammensetzungen | |
| LU83028A1 (de) | Pharmazeutischer ansatz zur verwendung als schutz gegen akutes lungenoedem,anaphylaktischen schock und andere arten von schock sowie hyperfibrinolyse | |
| DE2112430A1 (de) | Pharmazeutische Zubereitung und Verfahren zu ihrer Herstellung | |
| DE2428409B2 (de) | S,S'-Bis-(3-hydroxy-4-hydroxymethyl-2-methyI-5-pyridylmethyl)-carbonodithioat, dessen pharmakologisch verträgliche Salze und Arzneimittel | |
| DE4136900C1 (enrdf_load_stackoverflow) | ||
| DE3634989C2 (de) | Verfahren zur Herstellung von substituierten Bisphenolen | |
| DE2858813C2 (enrdf_load_stackoverflow) | ||
| AT368132B (de) | Verfahren zur herstellung von neuen produkten bestehend aus fuer die therapeutische anwendung genuegend reinen isobuttersaeureaniliden | |
| DE2134899B2 (de) | Verwendung von N-Äthyl-norscopolaminmethobromid | |
| DE2521905C2 (de) | Arzneimittel zur cerebralen Durchblutungsförderung | |
| DE3324727C2 (enrdf_load_stackoverflow) | ||
| DE2230003A1 (de) | Neue nitrosoharnstoffderivate | |
| DE2544100A1 (de) | Arzneimittel mit einem gehalt an 2-naphthyl-buttersaeurederivaten | |
| DE2416302B2 (de) | Dimeres sowie trimeres silybin und deren n-methylglucaminsalz und verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel | |
| DE69922398T2 (de) | Phenantrenderivate mit medizinischer anwendung sowie dessen herstellungsverfahren | |
| DE2533140B2 (de) | Verwendung von D-Glucuronsäure bzw. deren γ -Lacton | |
| DE2113489B2 (de) | 2-Nitro-benzofuranderivate, ein Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel | |
| DE2935329A1 (de) | 1-methyl-piperidin-4-ol-ester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| DE2307795C3 (de) | 11 beta 17alpha, 21 Trihydroxy-6 | |
| DE1620037A1 (de) | Verfahren zum Reinigen von Methdilazinsulfoxyd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| Q369 | Divided out of: |
Ref document number: 2725247 Country of ref document: DE |
|
| 8110 | Request for examination paragraph 44 | ||
| 8181 | Inventor (new situation) |
Free format text: ANTRAG AUF NICHTNENNUNG |
|
| AC | Divided out of |
Ref country code: DE Ref document number: 2725247 Format of ref document f/p: P |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |